Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
02:08a JUNO THERAPEUTICS, INC. (NASDAQ : JUNO) Files An 8-K Entry into a Material Defin..
09/23 CELGENE : Amended Collaboration Deal Gives Acceleron the Global Rights to Potent..
09/22 CELGENE : backed FLX picks CCR4 antagonist for clinical trials
09/21 ONCOLYTICS BIOTECH : reg; Announces First Patient Treated in MUK eleven Study
09/21 ACCELERON PHARMA : Showcases Vision and Strategy at 2017 R and D Day
09/21 ACCELERON PHARMA : to Develop Sotatercept in Pulmonary Arterial Hypertension
09/21 CELGENE : Acceleron takes back drug rights from Celgene to start pulmonary push
09/20 ONCOMED PHARMACEUTICALS : Chairman and CEO, Paul Hastings, to Take Medical Leave..
09/15 CELGENE : Gilead, Celgene and Biogen Are Ready To Rise
09/14 CELGENE : Provides Update on the Fusion™ Clinical Program
More news
News from SeekingAlpha
09/22 Juno prices stock offering at $41; shares up 1% premarket
09/21 FDA's Woodcock says clinical trials system "broken"
09/19 Biotech And Pharma Stocks To Soak Up At The Bottom
09/19 Acceleron tweaks Celgene agreement, to develop sotatercept for PAH
09/19 Will The Federal Reserve Send The Market Higher?
Financials ($)
Sales 2017 13 255 M
EBIT 2017 7 533 M
Net income 2017 4 346 M
Debt 2017 3 767 M
Yield 2017 -
P/E ratio 2017 25,48
P/E ratio 2018 19,68
EV / Sales 2017 8,78x
EV / Sales 2018 7,18x
Capitalization 113 B
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 153 $
Spread / Average Target 6,7%
EPS Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN27.65%135 544
GILEAD SCIENCES15.37%108 744
ACTELION22.00%29 523